53531-69-4

Usage

Uses

Used in Organic Synthesis:
4-Bromobenzylsulfonyl chloride is used as a reagent for the introduction of the sulfonyl group into various organic compounds, facilitating the synthesis of a wide range of chemical products.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-Bromobenzylsulfonyl chloride is used as a key intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents.
Used in Agrochemical Synthesis:
4-Bromobenzylsulfonyl chloride is utilized as an intermediate in the synthesis of agrochemicals, aiding in the production of effective pesticides and other agricultural chemicals.
Used in Fine Chemicals Synthesis:
4-BROMOBENZYLSULFONYL CHLORIDE is employed in the synthesis of fine chemicals, which are high-purity chemicals used in various applications, including research, diagnostics, and specialty manufacturing.
Used in Biological and Biochemical Research:
4-Bromobenzylsulfonyl chloride is used as a potent and selective inhibitor of protein kinases, making it a valuable tool in biological and biochemical research for studying enzyme function and developing targeted therapies.
Used in Research and Development:
Due to its reactivity and potential applications, 4-Bromobenzylsulfonyl chloride is used in research and development for exploring new chemical reactions, discovering novel compounds, and advancing scientific knowledge in various fields.

InChI:InChI=1/C7H6BrClO2S/c8-7-3-1-6(2-4-7)5-12(9,10)11/h1-4H,5H2

Upstream product

• 19552-10-4 4-bromobenzyl mercaptan 
• 237763-11-0 methanesulfonic acid 4-bromo-benzyl ester 
• 351003-15-1 thioacetic acid S-(4-bromo-benzyl)ester 
• 913259-67-3 C₈H₉BrN₂S*ClH 
• 589-17-3 p-bromobenzyl chloride 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Downstream Products

• 64732-38-3 1-(4-bromophenyl)methanesulfonamide 
• 172517-39-4 1-(4-bromophenyl)-N-methylmethanesulfonamide 
• 803727-98-2 N,N-bis(2,4-dimethoxybenzyl)-1,1-difluoro-1-(4-bromophenyl)methanesulfonamide 
• 1103941-55-4 C₂₀H₂₃BrN₄O₆S 
• 1103941-60-1 Boc-Arg(4-Bbs) 
• 1099831-25-0 C₂₀H₁₈BrNO₂S 
• 950253-98-2 C₁₄H₁₄BrNO₂S 
• 950229-48-8 C₁₂H₁₇BrN₂O₂S 
• 1298109-23-5 C₁₃H₇BrF₅NO₂S 
• 1298109-34-8 C₁₈H₁₃BrF₅NO₄S 
• 1397322-17-6 1-(4-bromophenyl)-2-hydroxy-2-methylpropane-1-sulfonamide 
• 1397322-18-7 5-(4-bromophenyl)-2-methoxy-6,6-dimethyl-5,6-dihydro-[1,4,3]-oxathiazine-4,4-dioxide 
• 1397322-15-4 C-(4-bromophenyl)-N-(2,4-dimethoxybenzyl)methanesulfonamide 
• 1397322-16-5 N-(2,4-dimethoxybenzyl)-1-(4-bromophenyl)-2-hydroxy-2-methylpropane-1-sulfonamide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors

Deregulation of receptor tyrosine kinase c-Met has been reported in human cancers and is considered as an attractive target for small molecule drug discovery. In this study, a series of 4-phenoxyquinoline derivatives bearing sulfonylurea moiety were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against tested four cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant potency as compared with foretinib, with the most promising compound 13x (c-Met kinase IC50 = 1.98 nM) demonstrated relatively good selectivity versus 10 other tyrosine kinases and remarkable cytotoxicities against HT460, MKN-45, HT-29 and MDA-MB-231 with IC50 values of 0.055 μM, 0.064 μM, 0.16 μM and 0.49 μM, respectively. The preliminary structure activity relationships indicated that a sulfonylurea moiety as linker as well as mono-EGWs (such as R1 = 4-F) on the terminal phenyl rings contributed to the antitumor activity.

Method for rapidly preparing abscisic acid receptor stimulant

The invention discloses a method for rapidly preparing an abscisic acid receptor stimulant and relates to a chemical synthesis and plant growing regulation technology. The method is characterized in that the two-step one-pot strategy is adopted, 4-methylb

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

Design, Sustainable Synthesis, and Programmed Reactions of Templated N-Heteroaryl-Fused Vinyl Sultams

A de novo design and synthesis of N-heteroaryl-fused vinyl sultams as templates for programming chemical reactions on vinyl sultam periphery or (hetero)aryl ring is described. The key features include rational designing and sustainable synthesis of the template, customized reactions of vinyl sultams at C=C bond or involving N-S bond cleavage, and reactions on the periphery of the heteroaryl ring for late-stage diversification. The simple, easy access to the template coupled with opportunities for the synthesis of diversely functionalized heterocyles from a single template constitutes a rare study in contemporary organic synthesis.

BENZENE SULFONAMIDE DERIVATIVES AND THEIR USE AS RORC MODULATORS

Compounds of the formula la or lb: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, D, E, G, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS

Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS

Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, r, A, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6